Form 4: Esperion Therapeutics Director Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


J Martin Carroll, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.

Summary

  • Disposition to the issuer: disposed of 177,523 Common Stock on July 13, 2026 (Direct).
  • Disposition to the issuer: disposed of 21,000 Stock Option (right to buy) on July 13, 2026 (Direct).
  • Disposition to the issuer: disposed of 32,500 Stock Option (right to buy) on July 13, 2026 (Direct).
  • Disposition to the issuer: disposed of 44,000 Stock Option (right to buy) on July 13, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

J Martin Carroll — Director

DateTransactionSecuritySharesPriceValueHeld After
2026-07-13Disposition to the issuerCommon Stock177,523——0
2026-07-13Disposition to the issuerStock Option (right to buy)21,000——0
2026-07-13Disposition to the issuerStock Option (right to buy)32,500——0
2026-07-13Disposition to the issuerStock Option (right to buy)44,000——0

Key Dates

DateDescription
2026-07-13Disposition to the issuer (177,523 shares)
2026-07-13Disposition to the issuer (21,000 shares)
2026-07-13Disposition to the issuer (32,500 shares)
2026-07-13Disposition to the issuer (44,000 shares)

Keywords

insider transaction, Form 4, ESPR, Esperion Therapeutics, Inc., neutral, J Martin Carroll

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.